Xerostomia Therapeutics Market Analysis

Treatment Type Analysis

The salivary stimulants segment is anticipated to register the largest share of 42.8% in the market during the forecast period.  The dominance of this segment is highly attributed to the continuous and rigorous occurrence of Sjögren’s syndrome among the worldwide population. According to data published by the National Institutes of Health in 2023, 4 million people were living with Sjögren’s syndrome. Government organizations such as the FDA prioritized chewable cevimeline, extending its contribution for the segment’s leadership by reducing dosing frequency and improving compliance.

Drug Class Segment Analysis

The cholinergic agonists segment is projected to register considerable growth in the xerostomia therapeutics market by 2035. The growth in the segment is primarily subject to its affordability, the aging demographics, and the generic boom in emerging countries. Doctors are considering the drug as 1^st line treatment in the emerging markets, owing to the low cost of dosages. Companies such as Sun Pharma and CSPC Pharma control a major part of Asia’s pilocarpine supply with a focus on cutting prices. These factors are propelling the demand for the segment during the forecasted period.

Distribution Channel Segment Analysis

Among the distribution channels, retail pharmacies are predicted to hold the largest share of 52% by 2035. This dominance of the sub-segment is propelled by their widespread accessibility, presence in both urban and rural areas. Also, the ability to provide both over-the-counter and prescription products makes retail pharmacies the preferred choice for most patients. The sub-segment growth is also attributed to the presence of robust supply chain relationships. This makes the retail pharmacies a go-to channel for users who are seeing therapeutics related to xerostomia. 

Our in-depth analysis of the global market includes the following segments: